This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Vertex Pharma

Stocks in this article: VRTX GILD ANX OPXA ARQL VRUS ITMN

BOSTON ( TheStreet) -- Vertex Pharmaceuticals (VRTX) will release results from the first phase III study of its experimental hepatitis C drug telaprevir sometime this quarter. I'm starting to get a bunch of email about expectations for the telaprevir data, including this message from Sanjin M., who asks:

" Any guesses on what to expect from Vertex Pharmaceuticals when it announces phase III hepatitis C test results? Will the stock go higher if the data are positive?"


I want to dive into this topic in more detail next week (assuming I'm not too late and Vertex announces top-line results), but just in case that happens, here's a quick cheat sheet on expectations for Vertex's telaprevir phase III studies in hepatitis C:

The first telaprevir data we're going to see comes from the phase III study known as ADVANCE, which enrolled treatment-naïve hepatitis C patients. Unlike most phase III studies, investors assume 100% that telaprevir works and that the ADVANCE study will be positive. The $8 billion question (Vertex's current market cap) is how well will telaprevir work? (i.e., by what magnitude will treatment with telaprevir improve the cure rate for hepatitis C patients?)

Right now, my best read on Street expectations is for telaprevir to demonstrate hepatitis C cure rates (the Hep C jargon is "SVR") in the 70-75% range compared to a cure rate in control patients in the mid-40% range.

Vertex's stock price in the low $40s basically bakes in a telaprevir cure rate of 70-75%, so I don't expect the stock to move higher if the actual result hits that range. In fact, a number in the low 70s may actually cause the stock to sell off a bit. Call it a "sell on the news" reaction.

A cure rate for telaprevir with a "6" in front will be a disaster, causing Vertex to sell off a lot.

A telaprevir cure rate in the high 70% range, perhaps even something with an "8" in front, will be viewed very positively. Vertex's stock price could move higher on that kind of data.

None of these predictions are set in stone and I should warn everyone that expectations for the telaprevir data are very high, so I may be totally underestimating the way investors will react.

1 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,779.11 +0.96 0.01%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs